Magnitude of the white-coat hypertension in the community pharmacy

Experimental and Clinical Cardiology

Volumn 20, Issue 1, 2014, Pages 2909-2936

  Chung, Chang Min ^a,b,c   Hsu, Jen Te ^a,b,c   Chang, Chia Hao ^b   Pan, Kuo Li ^a,b,c   Huang, Tung Jung ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^c CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

ABPM; HBPM; White coat hypertension, community pharmacy, sustained hypertension

Indexed keywords

ALBUMIN; ANTILIPEMIC AGENT;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD SAMPLING; BODY MASS; DIASTOLIC BLOOD PRESSURE; FEMALE; FOLLOW UP; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MASKED HYPERTENSION; MEDICAL HISTORY; PHARMACIST; PHARMACY; PHYSICAL EXAMINATION; PREVALENCE; SYSTOLIC BLOOD PRESSURE; WAIST HIP RATIO; WHITE COAT HYPERTENSION;

EID: 84900530444     PISSN: 12056626     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Mancia G, Grassi G, Pomidossi G, et al. Effects of blood pressure measurement by the doctor on patient's blood pressure and heart rate. Lancet 1983;2:695-8.
2. Pickering TG, Miller NH, Ogedegbe G, et al. American Heart Association; American Society of Hypertension; Preventive Cardiovascular Nurses Association. Call to action on use and reimbursement for home blood pressure monitoring: executive summary: a joint scientific statement from the American Heart Association, American Society of Hypertension, and Preventive Cardiovascular Nurses Association. Hypertension. 2008;52:1-9.
3. Pickering TG, Hall JE, Appel LJ, et al. Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Recommendations for blood pressure measurement in humans and experimental animals: Part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Hypertension. 2005;45:142-61.
4. Khattar RS, Senior R, Lahiri A. Cardiovascular outcome in white-coat versus sustained mild hypertension: a 10-year follow-up study. Circulation. 1998; 98:1892-7.
5. Celis H, Staessen JA, Thijs L, et al. Ambulatory Blood Pressure and Treatment of Hypertension Trial Investigators. Cardiovascular risk in white-coat and sustained hypertensive patients. Blood Press. 2002;11:352-6.
6. Kamel N, Gursoy A, Koseoglulari O, et al. Isolated office hypertension: association with target organ damage and cardiovascular risk indices. J Natl Med Assoc. 2006;98:601-6.
7. Glen SK, Elliott HL, Curzio JL, et al. White-coat hypertension as a cause of cardiovascular dysfunction. Lancet. 1996;348:654-7.
8. Ugajin T, Hozawa A, Ohkubo T, et al. White-coat hypertension as a risk factor for the development of home hypertension: the Ohasama study. Arch Intern Med. 2005;165:1541-6.
9. Björklund K, Lind L, Vessby B, et al. Different metabolic predictors of white-coat and sustained hypertension over a 20-year follow-up period: a population-based study of elderly men. Circulation. 2002;106:63-8.
10. Mancia G, Facchetti R, Bombelli M, et al. Long-term risk of mortality associated with selective and combined elevation in office, home, and ambulatory blood pressure. Hypertension. 2006;47:846-53.
11. Ohkubo T, Kikuya M, Metoki H, Asayama K, Obara T, Hashimoto J, Totsune K, Hoshi H, Satoh H, Imai Y. Prognosis of "masked" hypertension and "white-coat" hypertension detected by 24-h ambulatory blood pressure monitoring 10-year follow-up from the Ohasama study. J Am Coll Cardiol. 2005;46:508-515.
12. Verdecchia P, Reboldi GP, Angeli F, Schillaci G, Schwartz JE, Pickering TG, Imai Y, Ohkubo T, Kario K. Short- and long-term incidence of stroke in white-coat hypertension. Hypertension. 2005;45:203-208.
13. Fagard RH, Cornelissen VA. Incidence of cardiovascular events in whitecoat, masked and sustained hypertension versus true normotension: a meta-analysis. J Hypertens. 2007;25:2193-2198.
14. Franklin SS, Thijs L, Hansen TW, et al International Database on Ambulatory Blood Pressure in Relation to Cardiovascular Outcomes Investigators. Significance of white-coat hypertension in older persons with isolated systolic hypertension: a meta-analysis using the International Database on Ambulatory Blood Pressure Monitoring in Relation to Cardiovascular Outcomes population. Hypertension. 2012;59:564-571.
15. Llanes de Torres R, Aragón A, Sillero MI, Martín MD. Go to the health centre or go to pharmacy? Pharmacy offices as a primary care resource. Aten Primaria 2000; 26: 11-15.
16. Botomino A, Martina B, Ruf D, Bruppacher R, Hersberger KE. White coat effect and white coat hypertension in community pharmacy practice. Blood Press Monit 2005; 10:13-18.
17. Sabater-Hernández D, de la Sierra A, Sánchez-Villegas P, Baena MI, Amariles P, Faus MJ. Magnitude of the white-coat effect in the community pharmacy setting: the MEPAFAR study. Am J Hypertens. 2011;24(8):887-92.
18. Lindbaek M, Sandvik E, Liodden K, et al. Predictors of the white-coat effect in general practice patients with suspected and treated hypertension. Br J Gen Prac. 2003;53:790-3.
19. Mansoor GA, McCabe EJ, White WB. Determinants of the white-coat effect in hypertensive subjects. J Hum Hypertens. 1996;10:87-92.
20. Dolana E, Stantona A, Atkinsa N, et al. Determinants of white-coat hypertension. Blood Pressure Monitoring. 2004;9:307-9.
21. Khattar RS, Senior R, Lahiri A. Cardiovascular outcome in white-coat versus sustained mild hypertension: a 10-year follow-up study. Circulation. 1998;98:1892-7.
22. Pickering TG, James GD, Boddie C, et al. How common is white-coat hypertension? JAMA. 1988;259:225-8.
23. Verdecchia P, Porcellati C, Schillaci G, et al. Ambulatory blood pressure: an independent predictor of prognosis in essential hypertension. Hypertension. 1994;24:793-801.
24. Khattar RS, Senior R, Lahiri A. Cardiovascular outcome in white-coat versus sustained mild hypertension: a 10 year follow-up study. Circulation. 1998;98:1982-7.
25. Fagard RH, Staessen JA, Thijs L, et al. Response to antihypertensive therapy in older patients with sustained and nonsustained systolic hypertension. Circulation. 2000;102:1139-4.
26. Verdecchia P, Schillaci G, Borgioni C, et al. White-coat hypertension. Lancet. 1996;348:1444-5.
27. Dolan E, Stanton A, Thijs L, et al. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. Hypertension. 2005;46:156-61.
28. Perloff D, Sokolow M, Cowan R. The prognostic value of ambulatory blood pressures. JAMA. 1983;249:2792-8.
29. Ohkubo T, Imai Y, Tsuji I, et al. Prediction of mortality by ambulatory blood pressure monitoring versus screening blood pressure measurements: a pilot study in Ohasama. J Hypertens. 1997;15:357-64.
30. Bjorklund K, Lind L, Zethelius B, et al. Isolated ambulatory hypertension predicts cardiovascular morbidity in elderly men. Circulation. 2003;107:1297-302.
31. Clement DL, De Buyzere ML, De Bacquer DA, et al. Office versus Ambulatory Pressure Study Investigators. Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. N Engl J Med. 2003;348:2407-15.
32. Kario K, Pickering TG, Umeda Y, et al. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. Circulation. 2003;10:1401-6.
33. White WB. Ambulatory blood pressure monitoring for the assessment of antihypertensive therapy in clinical trials. In: White WB, editor. Blood pressure monitoring in cardiovascular medicine and therapeutics. Totowa, New Jersey: Springer-Verlag/Humana Press, Ltd; 2007. p.437-62.
34. White WB, Giles T, Bakris GL, et al. Measuring the efficacy of antihypertensive therapy by ambulatory blood pressure monitoring in the primary care setting. Am Heart J. 2006;151:176-84.
35. White WB, Mansoor GA, Pickering TG, et al. Differential effects of morning and evening dosing of nisoldipine ER on circadian blood pressure and heart rate. Am J Hypertens. 1999;12:806-14.
36. Sabater-Hernández D, de la Sierra A, Sánchez-Villegas P, Santana-Pérez FM, Merino-Barber L, Faus MJ. Agreement between community pharmacy and ambulatory and home blood pressure measurement methods to assess the effectiveness of antihypertensive treatment: the MEPAFAR study. J Clin Hypertens (Greenwich). 2012;14(4):236-44. Available at: http://onlinelibrary. wiley.com/doi/10.1111/j.1751-7176.2012.00598.x/pdf. Accessed June 27, 2012.
37. Sendra-Lillo J, Sabater-Hernández D, Sendra-Ortolá A, Martínez-Martínez F. Agreement between community pharmacy, physician's office, and home blood pressure measurement methods: the Palmera study. Am J Hypertens. 2012;25(3):290-96.
38. Sendra-Lillo J, Sabater-Hernández D, Sendra-Ortola A, Martínez-Martínez F. Comparison of the white-coat effect in community pharmacy versus the physician's office: the Palmera study. Blood Press Monit. 2011;16(2):62-66.
39. Sabater-Hernández D, Sánchez-Villegas P, Lacampa P, Artiles-Campelo A, Jorge-Rodríguez ME, Faus MJ. Evaluation of the hypertensive state in treated patients: selection of appropriate blood pressure measurements per visit to the community pharmacy. Blood Press Monit. 2011;16(3):103-10.
40. Sabater-Hernández D, Sánchez-Villegas P, García-Corpas JP, Amariles P, Sendra-Lillo J, Faus MJ. Predictors of the community pharmacy white-coat effect in treated hypertensive patients. The MEPAFAR study. Int J Clin Pharm.2011;33(3):582-89.